IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
JW LIFESCIENCE CORPORATION A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.	South Korea	234080
JW SHINYAK CORPORATION Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.	South Korea	067290
Jyong Biotech Ltd. Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.	United States of America	MENS
Kadimastem Ltd. Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.	Israel	KDST
kainos loboratories,inc Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.	Japan	4556
Kairos Pharma, LTD. Develops novel oncology therapies to reverse drug resistance and immune suppression.	United States of America	KAPA
KAKEN PHARMACEUTIAL CO., LTD. R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.	Japan	4521
KALA BIO, Inc. Developing stem cell-based biologics for rare and serious eye diseases.	United States of America	KALA
Kalaris Therapeutics, Inc. Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.	United States of America	KLRS
KalVista Pharmaceuticals, Inc. Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).	United States of America	KALV